Search clinical trials for: Membrane Transport Modulators

Total 23446 results

Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation (KONTINUE)

Cystic Fibrosis

United States, France, Belgium, United Kingdom
Duke University
Gilead Sciences

Completed

Ranolazine for the Treatment of Chest Pain in HCM Patients (RHYME)

Hypertrophic Cardiomyopathy

United States
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation

Cystic Fibrosis

United States, United Kingdom, Canada
Westside Medical Associates of Los Angeles
Gilead Sciences

Unknown

Impact of Ranolazine on Myocardial Ischemia Detected by High-Field 3T Cardiovascular Magnetic Resonance (CMR) Imaging and P-31 Spectroscopy

Heart Disease | Angina

United States
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation (STRIVE)

Cystic Fibrosis

United States, Canada, Australia, Ireland, France, United Kingdom, Germany, Czech Republic
Gilead Sciences

Terminated

A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine

Severe Renal Impairment

United States
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation (ENVISION)

Cystic Fibrosis

United States, Australia, Canada, France, Germany, Ireland, United Kingdom
Aspirus Heart and Vascular Institute-Research and...

Completed

Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction

Sudden Cardiac Death | Ventricular Arrythmias

United States
University of North Carolina, Chapel Hill
Takeda

Completed

Lubiprostone Effects on Visceral Pain Sensitivity

Irritable Bowel Syndrome

United States
Institut Straumann AG

Completed

Comparison of a PEG Membrane and a Collagen Membrane for the Treatment of Bone Dehiscence Defects at Bone Level Implants

Degeneration; Bone

Germany, Hungary, Belgium, Italy, Spain, Sweden, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation

Cystic Fibrosis

United States, Canada, Australia, Ireland, Germany, United Kingdom
Vanderbilt University Medical Center

Enrolling by invitation

Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy (REACT)

Crohn's Disease | Inflammatory Bowel Disease

United States
University of Alabama at Birmingham

Withdrawn

VX-770 for the Treatment of Chronic Bronchitis

Chronic Bronchitis

United States
University Medical Centre Ljubljana

Completed

A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy (RAMP-DCM)

Dilated Cardiomyopathy

Slovenia
Intermountain Health Care, Inc.
Gilead Sciences

Terminated

The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure (RAD HF)

Heart Failure | Atrial Fibrillation

United States
Walter Reed National Military Medical Center

Unknown

Study to Reduce Symptoms of Premature Beats With Ranolazine (RSVP)

Premature Ventricular Beats

United States
Sucampo Pharma Americas, LLC
Sucampo AG

Completed

Lubiprostone in Children With Functional Constipation

Constipation - Functional

United States, United Kingdom, Canada, Netherlands, Poland, Belgium, France
Sucampo Pharma Americas, LLC
Takeda; Sucampo AG

Terminated

Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
University of California, San Diego

Terminated

Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction

Diastolic Heart Failure | Echocardiography | Ranolazine | Tissue Doppler Ultrasound

United States
Cedars-Sinai Medical Center
University of Florida

Completed

Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia (RWISE)

Microvascular Coronary Dysfunction (MCD)

United States
Ohio State University
Gilead Sciences

Completed

Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1

Myotonic Dystrophy 1 | Myotonia Congenita | Paramyotonia Congenita

United States
Texas Tech University Health Sciences Center, El...

Completed

Lubiprostone and Mucus Secretion in Patients With Chronic Constipation

Constipation

United States
Amit Malhotra, MD
Gilead Sciences

Unknown

Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR) (REPTAR)

Angina

United States
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Terminated

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation (DISCOVER)

Cystic Fibrosis

United States
Tel-Aviv Sourasky Medical Center

Unknown

Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine

Long QT Syndrome Type 3

Israel
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-770 on Desipramine

In Development for Cystic Fibrosis

United States
Gilead Sciences
The TIMI Study Group

Completed

Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes

Myocardial Ischemia

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation

Cystic Fibrosis

United States, Canada, United Kingdom, Australia, Ireland
Midwest Cardiovascular Research Foundation
Gilead Sciences

Completed

Ranolazine in Ischemic Cardiomyopathy

Chest Pain | Dyspnea | Cardiomyopathy

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation

Cystic Fibrosis

Israel
Kent Hospital, Rhode Island
Gilead Sciences

Completed

Ranolazine Mediated PVC Reduction in Ischemic Heart Disease

Myocardial Ischemia | Ventricular Premature Complexes

United States
Cedars-Sinai Medical Center
CV Therapeutics

Completed

Microvascular Coronary Disease In Women: Impact Of Ranolazine

Myocardial Ischemia

United States
Emory University
Gilead Sciences

Completed

Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA) (MARINA)

Microvascular Angina

United States
University of Pennsylvania
University of Maryland; Gilead Sciences; Brigham and Women's Hospital

Completed

Targeting Right Ventricle in Pulmonary Hypertension Gilead

Pulmonary Hypertension

United States
University of Pennsylvania
Washington University School of Medicine; Yale University; University of Maryland and other collaborators

Completed

Targeting the Right Ventricle in Pulmonary Hypertension

Pulmonary Hypertension

United States
Vertex Pharmaceuticals Incorporated

Approved for marketing

Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis

Cystic Fibrosis
Northwestern University
Gilead Sciences

Completed

Ranolazine and Pulmonary Hypertension

Pulmonary Arterial Hypertension | Angina

United States
University of Louisville
Takeda

Completed

Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit

Constipation

United States
University of Arkansas
Takeda

Terminated

Lubiprostone as a Treatment for Constipation in Parkinson's Disease

Parkinson's Disease | Constipation

United States
GlaxoSmithKline
Bausch Health Americas, Inc.

Completed

Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy (RESTORE1)

Seizures

United States, Canada, Argentina, Brazil, Mexico
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation (KONNECTION)

Cystic Fibrosis

United States, France, Belgium
GlaxoSmithKline

Completed

Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures (IR)

Epilepsy

Bulgaria, Belgium, Thailand, Denmark, Russian Federation, Italy, Spain, Ukraine, Netherlands, Germany, France, Poland
Gilead Sciences

Completed

An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)

Chronic Angina

United States
Medical University of Vienna

Not yet recruiting

Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients

Urolithiasis | Hyperoxaluria

Austria
Astellas Pharma Europe B.V.

Completed

Drug to Drug Interaction Study With Ipragliflozin and Furosemide

Healthy Subjects | Pharmacokinetics of Ipragliflozin

United Kingdom
John Elfar

Not yet recruiting

4AP to Delay Carpal Tunnel Release (CTR) (CTR)

Carpal Tunnel Syndrome | Compression Neuropathy
University of Rochester
Gilead Sciences

Completed

Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients

Long QT Syndrome

United States
Danish Headache Center

Completed

Phenytoin as Treatment for Acute Exacerbations of Trigeminal Neuralgia - a Prospective Systematic Study of 20 Patients

Trigeminal Neuralgia

Denmark
Vertex Pharmaceuticals Incorporated

Completed

Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study) (VOCAL)

Cystic Fibrosis

Netherlands, Italy, United Kingdom

Search clinical trials for: Membrane Transport Modulators

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations